Premium
Janus kinase inhibitors for autoimmune disorders
Author(s) -
Chaplin Steve
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1635
Subject(s) - ruxolitinib , tofacitinib , medicine , janus kinase , rheumatoid arthritis , myelofibrosis , janus kinase inhibitor , janus kinase 2 , immunology , receptor , bone marrow , cytokine
Three janus kinase (JAK) inhibitors ‐ baricitinib (Olumiant) and tofacitinib (Xeljanz) for rheumatoid arthritis, and ruxolitinib (Jakavi) for myelofibrosis ‐ have already been launched in the UK and others are currently being evaluated in a diverse range of autoimmune disorders and cancers. This article provides an overview of the properties and potential of this new class of drugs.